|
|
Article: BioVex Gets $22 Million In Series E First Close.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
BioVex Inc. raised $22 million in the first close of its Series E financing to complete ongoing Phase I/II and Phase II trials with the oncolytic virus OncoVEX GM-CSF, to move the program into Phase III trials and to advance a second program into the clinic.
Philip Astley-Sparke, president and CEO of Woburn, Mass.-based BioVex, said the second close of the Series E, which may generate up to $8 million in additional funding, is expected in about two months.
Triathlon Medical Ventures led the round, with participation by new investor New Science Ventures LLC as well as existing investors ABN AMRO Capital Life Sciences (now Forbion ...